Ampio Pharma Reports Encouraging Results From Ampion 6-week Study - Quick Facts

(RTTNews) - Ampio Pharmaceuticals, Inc. (AMPE) announced the 6 weeks results of the open label portion of the multiple injections of Ampion into the knees of patients with osteoarthritis (OA). The first part of the multiple injection study involved patients receiving a series of three 4ml injections of Ampion intra-articularly (at baseline, 2 weeks and four weeks). The WOMAC A pain score improved by 86 % from baseline in the multiple injections study at 6 weeks following the first injection. The company said there were no drug related serious adverse events reported during the first 6 weeks of the current trial.

Macaluso, Ampio's CEO, said: "The results so far are very encouraging. All patients are reporting almost complete resolution of pain at week 6 and major improvement in function. Baseline MRI's and synovial fluid analysis for each patient performed just prior to the start of the injections, will be repeated at week 12 and compared to baseline to explore whether there are additional clinical benefits beyond pain relief and improved function."